NEW YORK (GenomeWeb) – Cancer Genetics reported today that total first quarter 2015 revenues more than tripled year over year.

The Rutherford, New Jersey-based firm said that for the first three months of 2015 it took in $4.4 million in total revenues, up from $1.4 million in the year ago quarter, due to a revenue contribution from acquisitions and an increase in volume of the firm's SelectOne clinical trials services. Revenues were in line with the consensus Wall Street estimate of $4.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.